By restoring impaired NO-sGC-cGMP signaling through distinct mechanisms, these agents may offer complementary therapeutic options for different CKD types and inform future clinical trial design.<h4>Systematic review registration</h4>The present study has been registered on PROSPERO (Registration No. CRD420251162902). This evidence concerns the gene SGCB and chronic kidney disease.